EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reduction in Respiratory Syncytial Virus (RSV)‐Related Outpatient and Inpatient Cases Among Infants During the Initial 2024/2025 Season Following Nirsevimab Recommendation in Germany

Wei Cai iD, Isabelle Maronde iD, Sophie Köndgen iD, Barbara Biere iD, Silke Buda iD, Brunhilde Schweiger iD, Doreen Staat iD, Walter Haas, Ekkehard Schuler, Virologic SARI Surveillance Study Group, Thorsten Wolff iD, Ralf Dürrwald iD und 3 weitere

Influenza and Other Respiratory Viruses · 2026-06 · 20 (6)

DOI: 10.1111/irv.70274 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, online erschienen am 17.06.2026. Verfasst von Wei Cai und 14 weiteren Autor:innen. Beteiligte Einrichtung: Unit 36, Respiratory Infections, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human, Antiviral Agents. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Robert Koch Institut, Bundesministerium für Gesundheit, European Centre for Disease Prevention and Control.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

After introducing nirsevimab during the 2024/2025 respiratory syncytial virus (RSV) season in Germany, RSV activity in infants under 1 year dropped by 50% in primary care and 50%–70% in secondary care. Inpatients under 6 months showed the greatest reduction. RSV severity decreased with fewer RSV‐associated ICU admissions and shorter hospital stays. RSV sequence analysis identified four known polymorphisms in the nirsevimab binding site among inpatients; none associated with resistance. These findings indicate that nirsevimab effectively reduced medically attended RSV disease in infants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus, HumanAntiviral AgentsHumansGermanyInfantInpatientsOutpatientsSeasonsHospitalizationFemale

Stichwörter der Autor:innen

disease severityhospitalisedinfantsnirsevimaboutpatientresistant mutationsrespiratory syncytial virussurveillance

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Unit 36, Respiratory Infections, Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
  • Unit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Influenza Centre, Robert Koch Institute, Berlin, Germany.
  • Unit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, Consultant Laboratory for RSV, PIV and HMPV, Robert Koch Institute, Berlin, Germany.
  • Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
  • HELIOS KLINIKEN GmbH, Berlin, Germany.

ORCID-Profile: Wei Cai, Isabelle Maronde, Sophie Köndgen, Barbara Biere, Silke Buda, Brunhilde Schweiger, Doreen Staat, Thorsten Wolff, Ralf Dürrwald, Djin-Ye Oh, Kristin Tolksdorf, Janine Reiche

Förderung

  • Robert Koch Institut
  • Bundesministerium für Gesundheit
  • European Centre for Disease Prevention and Control
  • Vaccine effectiveness, burden and impact studies

Zitieren

APA

Cai, W., Maronde, I., Köndgen, S., Biere, B., Buda, S., Schweiger, B., Staat, D., Haas, W., Schuler, E., Virologic SARI Surveillance Study Group, Wolff, T., Dürrwald, R., Oh, D. Y., Tolksdorf, K., & Reiche, J. (2026). Reduction in Respiratory Syncytial Virus (RSV)‐Related Outpatient and Inpatient Cases Among Infants During the Initial 2024/2025 Season Following Nirsevimab Recommendation in Germany. Influenza and Other Respiratory Viruses, 20(6). https://doi.org/10.1111/irv.70274

Vancouver

Cai W, Maronde I, Köndgen S, Biere B, Buda S, Schweiger B, et al. Reduction in Respiratory Syncytial Virus (RSV)‐Related Outpatient and Inpatient Cases Among Infants During the Initial 2024/2025 Season Following Nirsevimab Recommendation in Germany. Influenza and Other Respiratory Viruses. 2026;20(6). doi:10.1111/irv.70274

BibTeX
@article{Cai2026,
  author = {Cai, Wei and Maronde, Isabelle and Köndgen, Sophie and Biere, Barbara and Buda, Silke and Schweiger, Brunhilde and Staat, Doreen and Haas, Walter and Schuler, Ekkehard and Virologic SARI Surveillance Study Group, Virologic SARI Surveillance Study Group and Wolff, Thorsten and Dürrwald, Ralf and Oh, Djin-Ye and Tolksdorf, Kristin and Reiche, Janine},
  title = {Reduction in Respiratory Syncytial Virus (RSV)‐Related Outpatient and Inpatient Cases Among Infants During the Initial 2024/2025 Season Following Nirsevimab Recommendation in Germany},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2026},
  volume = {20},
  number = {6},
  doi = {10.1111/irv.70274}
}
Kostenlos starten →